Cited by 349Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies

Lambert, Mary P., Viola, Kirsten L., Chromy, Brett A., Chang, Lei, Morgan, Todd E., Yu, Jiaxin, Venton, Duane L., Krafft, Grant A., Finch, Caleb E., Klein, William L.·2001·Journal of Neurochemistry

DOI 10.1046/j.1471-4159.2001.00592.x

Open this paper in CoChat — free account

Abstract

In recent studies of transgenic models of Alzheimer's disease (AD), it has been reported that antibodies to aged beta amyloid peptide 1-42 (Abeta(1-42)) solutions (mixtures of Abeta monomers, oligomers and amyloid fibrils) cause conspicuous reduction of amyloid plaques and neurological improvement. In some cases, however, neurological improvement has been independent of obvious plaque reduction, and it has been suggested that immunization might neutralize soluble, non-fibrillar forms of Abeta. It is now known that Abeta toxicity resides not only in fibrils, but also in soluble protofibrils and oligomers. The current study has investigated the immune response to low doses of Abeta(1-42) oligomers and the characteristics of the antibodies they induce. Rabbits that were injected with Abeta(1-42) solutions containing only monomers and oligomers produced antibodies that preferentially bound to assembled forms of Abeta in immunoblots and in physiological solutions. The antibodies have proven useful for assays that can detect inhibitors of oligomer formation, for immunofluorescence localization of cell-attached oligomers to receptor-like puncta, and for immunoblots that show the presence of SDS-stable oligomers in Alzheimer's brain tissue. The antibodies, moreover, were found to neutralize the toxicity of soluble oligomers in cell culture. Results support the hypothesis that immunizations of transgenic mice derive therapeutic benefit from the immuno-neutralization of soluble Abeta-derived toxins. Analogous immuno-neutralization of oligomers in humans may be a key in AD vaccines.

Integrity signals

Registry

Crossref · 10.1046/j.1471-4159.2001.00592.x

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citation
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
High-Level Neuronal Expression of Aβ1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
MODELS OF AMYLOID SEEDING IN ALZHEIMER'S DISEASE AND SCRAPIE: Mechanistic Truths and Physiological Consequences of the Time-Dependent Solubility of Amyloid Proteins
Harper, J. D., & Lansbury, P. T. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.385 · Cited by 1,652
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,506
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state
Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
Lorenzo, A., & Yankner, B. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12243 · Cited by 1,324

Show all 45 references

Research works printed but not linked: 5

Guerette P. A., 2000, Oligomeric Aβ in PBS‐soluble extracts of human Alzheimer brain, Socneurosci. Abstract., 25, 2129
Kim K. S., 1990, Quantitation of amyloid β‐protein with two monoclonal antibodies, Neurosci. Res. Commun, 7, 113
Klein W. L., 2001, Molecular Mechanisms of Neurodegenerative Diseases, 1
Stine W. B., 2000, Amyloid beta 1–40 and 1–42: solubilization parameters and structural outcomes, Soc. Neurosci. Abstract., 26, 800
Terry R. D., 1999, Alzheimer Disease

Sorted by citations

Items 301–349 of 349

Chapter 4. Emerging themes in Alzheimer's disease research: Paradigm shift in drug discovery
Morgan, T. E., & Krafft, G. A. (2002) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(02)37005-2 · Cited by 3
Self-citation
Structure–Function Studies of Amyloid Pores in Alzheimer’s Disease as a Case Example of Neurodegenerative Diseases
Arce, F. T., Jang, H., Connelly, L. S., Ramachandran, S., Kagan, B. L., Nussinov, R., & Lal, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394431-3.00036-5 · Cited by 3
Mouse Model for Alzheimer’s Disease
Chishti, M. A., & Nakeeb, S. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-285-4_22 · Cited by 2
Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases
Olson, K. E., Mosley, R. L., & Gendelman, H. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_8 · Cited by 2
The role of syndapin-2 mediated transcytosis across the blood-brain barrier on amyloid-β accumulation in the brainPreprint
Leite, D. M., Seifi, M., Ruiz‐Pérez, L., Nguemo, F., Plomann, M., Swinny, J. D., & Battaglia, G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.12.199869 · Cited by 2
A genetically encoded selection for amyloid-β oligomer binders
Lee, B., Mannone, J. A., & Wang, T. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01975-4 · Cited by 3
Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation
Fallot, L. B., Anderson, C. A., Pinc, J. R., Stevenson, A., Schleck, M. C., Hawryschuk, E., Li, O. Z., Palchak, J. C., Toole, J. R., Kubiak, R. W., II, et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c01289 · Cited by 1
An Aβ concatemer with altered aggregation propensities
Giehm, L., Degan, F. D., Fraser, P. E., Klysner, S., & Otzen, D. E. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.06.023 · Cited by 1
Biological Targeting and Activity of Pre-fibrillar Aβ Assemblies
Wilcox, K. C., Pitt, J. E., Sebollela, A. S., Martirosova, H., Lacor, P. N., & Klein, W. L. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_4 · Cited by 1
Self-citation
Molecular Mechanism Underlying Aβ Immunotherapy: Implications for the Toxic Action of Aβ Oligomers
Matsubara, E. (2013) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.s2-001 · Cited by 1
The Importance of Vaccines in Preventing Impending Alzheimer’s Epidemic
Tripathi, S., Sharma, Y., & Kumar, D. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871357356250325071712 · Cited by 1
Interaction of Alzheimer Amyloid Peptide with Cell Surfaces and Artificial Membranes
Bateman, D. A., & Chakrabartty, A. (2011) · Wiley eBooks · doi:10.1002/9783527634323.ch11 · Cited by 1
Redox Proteomics Identification of Oxidatively Modified Proteins in Alzheimer’s Disease Brain and in Brain from a Rodent Model of Familial Parkinson’s Disease: Insights into Potential Mechanisms of Neurodegeneration
Rukhsana Sultana, A., Poon, H. F., & Butterfield, D. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_15 · Cited by 1
Yeast as a Model for Studying Aβ Aggregation, Toxicity and Clearance
Bharadwaj, P. (2011) · Australasian Journal of Paramedicine · Cited by 1
Antibody-based therapeutics
Tachibana, T., & Kuwabara, T. (2019) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2019.01.006 · Cited by 1
Peptide Vaccines
Muller, C. P., & Pütz, M. M. (2010) · Wiley eBooks · doi:10.1002/9780470688618.taw0123 · Cited by 1
Analysis of Reelin function in the molecular mechanisms underlying Alzheimer’s disease
Rossi, D. P. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Targeting Early Stages of Alzheimer’s Disease in a Transgenic Model
Lord, A. (2009) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Reporters of Amyloid Structure
LeVine, H. (2006) · Springer eBooks · doi:10.1007/0-387-25919-8_14
Effects of Adoptive Transfer of Beta-Amyloid Sensitive Immune Cells in a Mouse Model for Alzheimer’s Disease
Shippy, D. C. (2005) · Digital Commons - University of South Florida (University of South Florida)
Study of the aggregation process of the amyloid beta-protein associated to Alzheimer's disease. Examination of pharmaceutically important small molecules.
Vidal, B. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Endosomes élargis et cholestérol : De la trisomie 21 à la maladie d'Alzheimer
Cossec, J. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique)
The a₁-antichymotrypsin-51bp promoter polymorphism : functional activity and its role in Alzheimer's disease
Ritchie, A. (2004) · Nottingham ePrints (University of Nottingham)
Listening to the Song of Senescence
Chen, I. (2003) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2003.5.nf3
Antibody Based Therapeutics for Alzheimer's Disease
Boddapati, S. P. (2011)
Estrogen-induced Signaling Links Structural and Functional Synaptic Plasticity
Logan, S. M. (2009)
Oligomeric amyloid-beta as a potential biomarker for Alzheimer's disease
Venkataraman, L. (2013)
Alzheimer disease: Studies on Aand -secretase in human brain
Welander, H. (2009)
Aβ Conformation Dependent Antibodies and Alzheimer's Disease
Sehlin, D. (2010) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
VARIANCE OF THE AMYLOID BETA PEPTIDE AS A METRIC FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE
Beckett, C. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2016.161
Studying Amyloid b-Protein Assembly
Maji, S. K., Lazo, N. D., Fradinger, E. A., & Teplow, D. B. (2004) · CRC Press eBooks · doi:10.1201/9780203492185.ch7
Membrane Interaction of Alzheimer's Beta Peptides
Wu, H., Marquardt, D., Harroun, T. A., & Bradshaw, J. (2013)
AO IS AEW ERA OF MEDICAL HISTORYA REVIEW
Kumar, R., Bakrudeen, A., & Ahmed, A. (2009)
GM1 mediates the formation and maintenance of cytotoxic Aβ oligomersPreprint
Zhang, D. Y., Wang, J., Fleeman, R. M., Kuhn, M. K., Swulius, M. T., Proctor, E. A., & Dokholyan, N. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.22.453392
Anti-Aging Medicine LiteratureWatch
(2002) · Rejuvenation Research · doi:10.1089/109454502317629363
Can motional dynamics account for the cytotoxicity of beta amyloid oligomers?Preprint
Yeh, C., Chang, H., Hsu, W.-H., Huang, S., Wu, M., Tu, L., Lee, M., & Chan, J. C. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.04.539338
Imaging Aβ aggregation by liquid-phase transmission electron microscopyPreprint
Ing, G., Acosta‐Gutiérrez, S., Vendruscolo, M., Battaglia, G., & Ruiz‐Pérez, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.29.577710
Second Section: A single domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.05
References
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.references
Discussion
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.07
Third Section: Design of a dimeric-nanobody specific for Aβ42 oligomers: the Dimeric-DesAb-O
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.06
A multidisciplinary approach for the early diagnosis of Alzheimer’s disease and potential therapeutic applications
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9
Material and Methods
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.03
First Section: Putative CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.04
Introduction
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.02
Conclusion and Future Perspectives
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.08
Structure–Activity Relationship Study of Protoberberine Alkaloids Reveals Molecular Planarity as a Key Determinant of Membrane Interaction and Protection from Misfolded Protein Oligomers
Errico, S., Bigi, A., Fani, G., Ambrosino, M., Galmiche, E., Bemporad, F., Vendruscolo, M., Mannini, B., & Chiti, F. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01682
A new method for the production of recombinant human Aβ(1-42) peptide
Chen, P., Guo, L., Guo, X., Hong, W., & Meng, W. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106238
Amyloid precursor protein (APP) and copper homeostasis in the human neuroblastoma cell line SH-SY5Y
Klein, J. (2011)

Authors: Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., & Klein, W. L.
Affiliations: Northwestern University (US)
University of Southern California (US)
University of Illinois Chicago (US)
Corresponding author: Klein, William L.
ORCID: Viola, Kirsten L.
Chang, Lei
Morgan, Todd E.
Yu, Jiaxin
Finch, Caleb E.
Klein, William L.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 2001-11
Volume: 79
Issue: 3
Pages: 595-605
ISSN: 0022-3042 (ISSN-L)
1471-4159
DOI: 10.1046/j.1471-4159.2001.00592.x
OpenAlex: W1857351893
Cited by: 349
References: 45
Citations by year: 2026: 12 · 2025: 8 · 2024: 4 · 2023: 11 · 2022: 6 · 2021: 8 · 2020: 15 · 2019: 10 · 2018: 5 · 2017: 11 · 2016: 6 · 2015: 10 · 2014: 18 · 2013: 20 · 2012: 20
FWCI: 8.37
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2440 d)
Locations: Journal of Neurochemistry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
National Institute on Aging (AG-13499, P01 AG13138, R01AG013499)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Alzheimer's disease, amyloid-beta oligomers, amyloid-beta 42, immunization, neutralizing antibodies, amyloid plaques, amyloid protofibrils, oligomer toxicity, Alzheimer's disease vaccine, transgenic mice
MeSH terms: Alzheimer Disease, Animals, Antibody Specificity, Epitopes, Fluorescent Antibody Technique, Hippocampus, Humans, Neurons, Peptide Fragments, Solubility, Vaccination, Amyloid beta-Peptides, PC12 Cells, Neuroprotective Agents, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks